Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Acquisitions & Divestments (2021 - 2024)

BioNexus Gene Lab's Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $574036.0 for Q4 2024.

  • For Q4 2024, Change in Acquisitions & Divestments rose 81178.53% year-over-year to $574036.0; the TTM value through Mar 2025 reached $857433.0, up 261.04%, while the annual FY2024 figure was $1.1 million, 3987.73% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2024 was $574036.0 at BioNexus Gene Lab, up from $197063.0 in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $574036.0 in Q4 2024 and bottomed at -$708.0 in Q4 2023.
  • The 3-year median for Change in Acquisitions & Divestments is $56594.0 (2023), against an average of $136856.1.
  • The largest YoY upside for Change in Acquisitions & Divestments was 81178.53% in 2024 against a maximum downside of 633.83% in 2024.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at -$22.0 in 2021, then crashed by 3118.18% to -$708.0 in 2023, then skyrocketed by 81178.53% to $574036.0 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Change in Acquisitions & Divestments are $574036.0 (Q4 2024), $197063.0 (Q3 2024), and $86334.0 (Q2 2024).